DURECT Corp To Discuss Agreement Call Transcript
Greetings, and welcome to the DURECT Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to Mike Arenberg, Chief Financial Officer. Thank you. You may begin.
Good morning, and welcome to our call to discuss our license agreement with Innocoll Pharmaceuticals. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation.
Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding DURECT's products and development, expected product benefits, our development plans, future clinical trials, our projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in our SEC filings, including our 10-K and 10
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |